On April 1, 2020, the FDA announced a voluntary recall of ALL prescription and over-the-counter (OTC) ranitidine products for an ongoing investigation of an impurity (N-nitrosodimethylamine “NDMA”). NDMA is considered a probable carcinogen by the International Agency for Research on Cancer.
Dispensing retail pharmacies will contact patients whose prescriptions are affected. Your patients may contact you because they learn about the recall for their prescribed or OTC product and ask for a recommendation for an alternative medication.
If your clinic feels appropriate to contact patients possibly affected, there is the option for providers to generate EPIC reports to identify your patients on certain medications.
Ranitidine Dosage Conversion Table
MyHealth Smart Phrase Bulk Patient Message Example
Your records indicate that you are currently taking Ranitidine, also known as Zantac, which is available as prescription and over-the-counter.
On April 1, 2020, the FDA announced a voluntary recall of ALL ranitidine products for an ongoing investigation of an impurity (N-nitrosodimethylamine “NDMA”). The FDA did not observe any unacceptable levels of NDMA in any tested ranitidine samples, but are being proactive and cautious with the voluntary recall of all ranitidine products. The FDA does not expect NDMA to cause harm when ingested at low levels.
For more information on this recall, please refer to: https://www.fda.gov/safety/medical-product-safety-information/all-ranitidine-products-zantac-press-release-fda-requests-removal
Your Stanford primary care physician recommends that you STOP taking ranitidine. Should you need a replacement, you can substitute with an alternative that does NOT carry the same risks from NDMA. To date, the FDA’s testing has not found NDMA in famotidine, also known as Pepcid (available over-the-counter).
If you are taking:
If you cannot take or tolerate famotidine (Pepcid) or have additional questions, please contact your primary care provider.